A plain language summary of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated NSCLC who received amivantamab

A Plain Language Summary of Publication, which was recently published in Future Oncology, describes the CHRYSALIS study for those who wish to know more about NSCLC with EGFR exon 20 insertion mutations.  Abstract What is this summary about? This is a plain language summary of an article published in the Journal of Clinical Oncology in 2021. It describes the first results from 1 group of patients in the Phase I CHRYSALIS study with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations. This part of the CHRYSALIS study (called cohort D) investigated the bispecific antibody amivantamab in patients with non-small-cell...